Quest Diagnostics (NYSE:DGX) CEO J. Davis Sells 10,000 Shares

Posted by Geri Gentry on Sep 4th, 2026

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) CEO J. Davis sold 10,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total value of $2,427,200.00. Following the completion of the sale, the chief executive officer directly owned 122,423 shares in the company, valued at approximately $29,714,510.56. This represents a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Quest Diagnostics Price Performance

DGX opened at $239.60 on Friday. The stock has a 50-day moving average price of $227.10 and a 200-day moving average price of $208.11. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market cap of $26.44 billion, a PE ratio of 25.44, a P/E/G ratio of 2.20 and a beta of 0.55. Quest Diagnostics Incorporated has a 1 year low of $171.18 and a 1 year high of $247.19.

Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. Quest Diagnostics’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Sell-side analysts predict that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.4%. Quest Diagnostics’s dividend payout ratio is presently 36.52%.

Analyst Ratings Changes

DGX has been the subject of a number of recent analyst reports. Mizuho boosted their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Truist Financial increased their target price on Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Argus set a $260.00 target price on Quest Diagnostics in a report on Wednesday, July 29th. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 28th. Finally, UBS Group upped their price target on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.31.

Get Our Latest Research Report on Quest Diagnostics

Institutional Investors Weigh In On Quest Diagnostics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its stake in Quest Diagnostics by 22,733.0% during the 2nd quarter. California State Teachers Retirement System now owns 37,043,773 shares of the medical research company’s stock valued at $7,851,428,000 after buying an additional 36,881,535 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Quest Diagnostics in the 2nd quarter worth $1,965,923,000. Bank of America Corp DE bought a new stake in shares of Quest Diagnostics in the second quarter worth $410,151,000. Norges Bank bought a new stake in shares of Quest Diagnostics in the fourth quarter worth $229,522,000. Finally, Boston Partners grew its stake in shares of Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock valued at $767,978,000 after purchasing an additional 997,033 shares during the period. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.